The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Roivant Sciences Ltd shares valued at $4,384,000 were sold by Venker Eric on Jan 12 ’26. At $21.92 per share, Venker Eric sold 200,000 shares. The insider’s holdings dropped to 1,654,597 shares worth approximately $38.02 million following the completion of this transaction.
Also, Venker Eric purchased 200,000 shares, netting a total of over 4,383,694 in proceeds.
Before that, Sukhatme Mayukh had sold 1,018,995 shares from its account. In a trade valued at $22,122,381, the President & CIO traded Roivant Sciences Ltd shares for $21.71 each. Upon closing the transaction, the insider’s holdings decreased to 1,018,995 shares, worth approximately $465.75 million.
As published in their initiating research note from Citigroup on September 02, 2025, Roivant Sciences Ltd [ROIV] has been a Buy and the price target has been revised to $16. As of February 15, 2024, Wolfe Research has initiated its “an Outperform” rating for ROIV. Earlier on January 05, 2024, Piper Sandler initiated its rating. Their recommendation was “an Overweight” for ROIV stock.
Analyzing ROIV Stock Performance
The stock’s lowest price that day was $22.84, but it reached a high of $23.19 in the same session. During the last five days, there has been a drop of approximately -1.96%. Over the course of the year, Roivant Sciences Ltd shares have jumped approximately 106.10%.
Is Roivant Sciences Ltd subject to short interest?
Stocks of Roivant Sciences Ltd saw a sharp steep in short interest on 2025-12-31 dropping by -1.33 million shares to 19.58 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 20.91 million shares. A decline of -6.82% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.42 of the overall float, the days-to-cover ratio (short ratio) decline to 2.42.
Which companies own the most shares of Roivant Sciences Ltd (ROIV)?
In terms of Roivant Sciences Ltd share price expectations, FactSet research, analysts set an average price target of 27 in the next 12 months, up nearly 17.49% from the previous closing price of $22.98. Analysts anticipate Roivant Sciences Ltd stock to reach 32 by 2026, with the lowest price target being 20. In spite of this, 7 analysts ranked Roivant Sciences Ltd stock as Buy at the end of 2026. On December 12, 2023, Deutsche Bank assigned a price target of “a Buy” to the stock and initiated coverage with a $14.
